Highlights Alimera Sciences, Inc.

Equities

ALIM

US0162592028

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
3.555 ^USD	+5.18%		-2.60%	-17.71%

25/03	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT
19/03	Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network	19/03	CI
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	07/03	MT
Earnings Flash (ALIM) ALIMERA SCIENCES Posts Q4 Revenue $26.3M	07/03	MT
Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024	07/03	CI
Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
Alimera Completes Recruitment for the Synchronicity Study	04/01	CI
Alimera Announces Scientific Data Highlighting ILUVIEN to Be Presented at the American Academy of Ophthalmology	31/23/31	CI
Earnings Flash (ALIM) ALIMERA SCIENCES Reports Q3 Revenue $23.4M	26/23/26	MT
Alimera Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/23/26	CI
Earnings Flash (ALIM) ALIMERA SCIENCES Reports Q2 Revenue $17.5M	10/23/10	MT
Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
EyePoint Sells Yutiq Rights to Alimera Sciences for $82.5 Million	18/23/18	MT
Alimera Sciences, Inc. acquired YUTIQÂ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.	18/23/18	CI
Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.	18/23/18	CI
Earnings Flash (ALIM) ALIMERA SCIENCES Reports Q1 Revenue $13.5M, vs. Street Est of $12.3M	15/23/15	MT
Alimera Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Alimera Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Alimera Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	31/23/31	CI
Alimera Sciences, Inc. Announces Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIENÂ«Administration	29/22/29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alimera Sciences, Inc.

Equities

ALIM

US0162592028

Highlights

Filters